Chromosomal abnormality is a primary genetic factor that lead to azoospermia and male infertility. Here, we report the cases of two brothers with primary infertility, whose chromosomes displayed a balanced translocation, and their karyotypes were 46,Y, t(X; 1) (q28; q21). Both presented an azoospermia phenotype without abnormal clinical symptoms. Their mother's karyotype was 46,X, t(X; 1) (q28; q21), and their father's chromosome karyotype was 46,XY. No abnormal changes were noted in the copy number of chromosome fragments in the whole genome. This study is the first to report showing that 46,Y, t(X; 1) (q28; q21) chromosomal abnormalities are associated with azoospermia.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/and.13867 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Identification of t(X;1)(q28;q21) generating a novel GATAD2B::MTCP1 gene fusion in CMML and its persistence during progression to AML.
Hematology
December 2025
National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Soochow University, Suzhou, People's Republic of China.
Objective: Hematological malignancies often involve chromosomal translocations and fusion genes that drive disease progression. While is well-known in T-cell prolymphocytic leukemia (T-PLL), its role in myeloid neoplasms is less understood. This report presents the first identification of the t(X;1)(q28;q21) translocation leading to the fusion in acute myeloid leukemia (AML) transformed from chronic myelomonocytic leukemia (CMML).
View Article and Find Full Text PDFComprehensive analysis of three female patients with different types of X/Y translocations and literature review.
Mol Cytogenet
May 2023
Department of Medical Genetics & Prenatal Diagnosis Center, West China Second University Hospital, Sichuan University, No.20, South Section 3, Renmin Road, Chengdu, 610041, Sichuan, China.
Background: X/Y translocations are highly heterogeneity in terms of clinical genetic effects, and most patients lack complete pedigree analysis for clinical and genetic characterization.
Results: This study comprehensively analyzed the clinical and genetic characteristics of three new patients with X/Y translocations. Furthermore, cases with X/Y translocations reported in the literature and studies exploring the clinical genetic effects in patients with X/Y translocations were reviewed.
TAaCGH Suite for Detecting Cancer-Specific Copy Number Changes Using Topological Signatures.
Entropy (Basel)
June 2022
Department of Mathematics, NC State University, Raleigh, NC 27695, USA.
Copy number changes play an important role in the development of cancer and are commonly associated with changes in gene expression. Persistence curves, such as Betti curves, have been used to detect copy number changes; however, it is known these curves are unstable with respect to small perturbations in the data. We address the stability of lifespan and Betti curves by providing bounds on the distance between persistence curves of Vietoris-Rips filtrations built on data and slightly perturbed data in terms of the bottleneck distance.
View Article and Find Full Text PDFMDS/MPN-Unclassifiable with t(X;17)(q28;q21) and KANSL1-MTCP1/CMC4 Fusion Gene.
Cytogenet Genome Res
March 2022
Laboratory Medicine Program, University Health Network, and Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
Article Synopsis
- MDS/MPN-U is a type of blood disorder that doctors don’t fully understand yet.
- Recent research showed that different people with this disorder have different genetic changes.
- This report is special because it's the first time someone found a specific genetic change in a person with MDS/MPN-U that created a new gene combination.
Randomized phase II study of CPT-11 versus PTX versus each combination chemotherapy with S-1 for advanced gastric cancer that is refractory to S-1 or S-1 plus CDDP: OGSG0701.
Int J Clin Oncol
October 2021
Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, Suita, Japan.
Background: To compare irinotecan-alone, paclitaxel-alone, and each combination chemotherapy with S-1 in patients with advanced gastric cancer (AGC) that is refractory to S-1 or S-1 plus cisplatin (SP).
Methods: Patients with AGC after first-line chemotherapy with S-1 or SP, or patients during adjuvant chemotherapy or within 26 weeks after adjuvant chemotherapy completion with S-1 with confirmed disease progression were eligible. Patients were randomly divided into four groups based on treatment: irinotecan-alone (irinotecan; 150 mg/m, day 1, q14 days), paclitaxel-alone (paclitaxel; 80 mg/m, days 1, 8, 15, q28 days), S-1 plus irinotecan (irinotecan; 80 mg/m, days 1, 15, S-1; 80 mg/m, days 1-21, q35 days), and S-1 plus paclitaxel (paclitaxel; 50 mg/m, day1, 8, S-1; 80 mg/m, days 1-14, q21 days).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!